Adeza to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference; Webcast Scheduled Thursday, June 15 at 3:30 p.m. ET.

SUNNYVALE, Calif. -- Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson, president and chief executive officer, will make an investment community presentation at the Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference on Thursday, June 15 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time). The conference is being held at the New York Palace Hotel.

A live audio and slide webcast of the presentation will be available via the Internet by visiting the company's Web site at www.adeza.com. An archived presentation will be available on the Web site for 14 days.

Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, FullTerm(TM), The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility. In May 2006, Adeza announced the submission of a New Drug Application (NDA) with the FDA for Gestiva, a long-acting form of a naturally occurring progesterone to prevent preterm birth in women with a history of preterm delivery. Adeza's NDA submission includes data from a clinical study conducted by the National Institutes of Health. More information is available at www.adeza.com.

Adeza cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Adeza that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Adeza's business including, without limitation, statements about the expansion of the indications for its products. Further information about these and other risks is included in Adeza's Annual Report on Form 10-K and other periodic and current reports filed by Adeza with the Securities Exchange Commission, which are available from the SEC's Web site (www.sec.gov), and also available on the Investor Relations section of Adeza's Web site. All forward-looking statements are qualified in their entirety by this cautionary statement and Adeza undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.